초록 ▼

This invention is generally related to coatings for implantable medical devices, such as drug delivery vascular stents. The coating includes a drug reservoir layer above the outer surface of the device body, the drug reservoir layer with a peptide or protein, a hydrophobic drug, and a polymer with a

This invention is generally related to coatings for implantable medical devices, such as drug delivery vascular stents. The coating includes a drug reservoir layer above the outer surface of the device body, the drug reservoir layer with a peptide or protein, a hydrophobic drug, and a polymer with a weight average molecular weight between about 10,000 to about 150,000 Daltons. A preferred polymer is a poly(ester amide) polymer.

대표청구항 ▼

1. An implantable medical device comprising: a device body and a coating disposed over the device body, the coating comprising: a drug reservoir layer comprising: a peptide or protein;a hydrophobic drug; anda polymer with a weight average molecular weight between about 10 to about 150 K Daltons;wher

1. An implantable medical device comprising: a device body and a coating disposed over the device body, the coating comprising: a drug reservoir layer comprising: a peptide or protein;a hydrophobic drug; anda polymer with a weight average molecular weight between about 10 to about 150 K Daltons;wherein the mass ratio of the peptide or protein to the hydrophobic drug is from about 1:0.1 to about 1:10;wherein the mass ratio of the protein or peptide to the polymer is from about 1:0.1 to about 1:10;wherein the cumulative release of the peptide or protein from the drug reservoir layer is between about 5% and about 50% at 24 hours and between about 10% and about 95% at 7 days; andwherein the polymer is a poly(ester-amide) or a poly(amide) that is of the following formula: wherein:i is an integer from 1 to 10, inclusive;j is an integer from 0 to 10, inclusive;k is an integer from 0 to 15, inclusive;xn is an integer from 0 to 100, inclusive;ym is an integer from 0 to 150, inclusive;p is an integer from 2 to about 4500;Mw is from about 10,000 to about 1,000,000 Da;si, tj, and vk represent the average mole fraction of each of Ai, Bj, and Ck;si is a number from 0 to 0.5, inclusive;tj is a number from 0 to 0.5, inclusive;vk is a number from 0 to 0.5, inclusive;with the proviso that Σisi+Σjtj+Σkvk=1.0;Σisi=Σjtj+Σkvk=0.5;Σisi>0;Σjtj>0 or Σkvk>0;each Ai has the chemical structure: each Bj has the chemical structure and each Ck has the chemical structure: wherein:each Rbj, and Rbj′ are independently selected from the group consisting of hydrogen and (C1-C4)alkyl, wherein: the alkyl group is optionally substituted with a moiety selected from the group consisting of —OH, —SH, —SeH, —C(O)OH, —NHC(NH)NH2, phenyl and or one or more of Rbj and Rbj′ may form a bridge between the carbon to which it is attached and the adjacent nitrogen, the bridge comprising —CH2CH2CH2—;each Rai, and each Rcj are independently selected from the group consisting of (C1-C12)alkyl, (C2-C12)alkenyl, (C3-C8)cycloalkyl,-(CH2CH2O)CH2CH2— wherein q is an integer from 1 to 10, inclusive, and where z is 0, 1, or 2; subject to the restriction that at least one Rai is selected from the group consisting of where z is 0, 1, or 2; Rdk is selected from the group consisting of —H, —OH, —O(C1-C20)alkyl, —O(C1C20)alkenyl and —O(CH 2CH2O)wCH2CH2ORek, wherein: w is an integer from 1 to 600, inclusive;Rek is selected from the group consisting of hydrogen,—C(O)CH═CH2 and —C(O)C(CH3)═CH2; and,each Rai, corresponds to the ith Ai group, each Rbj, Rbj′ , and Rcj corresponds to the jth Bj group, and each Rdk and optionally Rek correspond to the kth Ck group. 2. The device of claim 1, wherein the implantable medical device is a stent. 3. The device of claim 1, wherein the cumulative release of the hydrophobic drug from the drug reservoir layer is between about 5% and about 50% at 24 hours and between about 10% and about 95% at 7 days. 4. The device of claim 1, wherein the cumulative release of the hydrophobic drug from the drug reservoir layer is between about 10% and about 35% at 24 hours and between about 25% and about 75% at 7 days. 5. The device of claim 1, wherein the mass ratio of the peptide or protein to the hydrophobic drug is from about 1:0.2 to 1:5. 6. The device of claim 1, wherein the mass ratio of the peptide or protein to the hydrophobic drug is from about 1:0.5 to 1:3. 7. The device of claim 1, wherein the mass ratio of the protein or peptide to the polymer is from about 1:0.2 to about 1:5. 8. The device of claim 1, wherein the mass ratio of the protein or peptide to the polymer is from about 1:2 to about 1:4. 9. An implantable medical device comprising: a device body and a coating disposed over the device body, the coating comprising: a drug reservoir layer comprising: a peptide or protein;a hydrophobic drug; anda polymer with a weight average molecular weight between about 10 to about 150 K Daltons;wherein the mass ratio of the peptide or protein to the hydrophobic drug is from about 1:0.1 to about 1:10;wherein the mass ratio of the protein or peptide to the polymer is from about 1:0.1 to about 1:10;wherein the cumulative release of the peptide or protein from the drug reservoir layer is between about 5% and about 50% at 24 hours and between about 10% and about 95% at 7 days;andwherein the polymer is a poly(ester-amide) or a poly(amide) that is of the following formula: wherein:i is an integer from 1 to 10, inclusive;j is an integer from 0 to 10, inclusive;k is an integer from 0 to 15, inclusive;xn is an integer from 0 to 100, inclusive;ym is an integer from 0 to 150, inclusive;p is an integer from 2 to about 4500;Mw is from about 10,000 to about 1,000,000 Da;si, tj, and vk represent the average mole fraction of each of Ai, Bj, and Ck;si is a number from 0 to 0.5, inclusive;tj is a number from 0 to 0.5, inclusive;vk is a number from 0 to 0.5, inclusive;with the proviso that Σisi+Σjtj+Σkvk=1.0;Σisi=Σjtj+Σkvk=0.5;Σisi>0;Σjtj>0 or Σkvk>0;each Ai has the chemical structure: each Bj has the chemical structure and each Ck has the chemical structure each Rai corresponds to the ith Ai group, each Rbj, Rbj′, and Rcj corresponds to the jth Bj group, andeach Rdk and optionally Rek correspond to the kth Ck group; andwherein i =1, j =2, k =0,Ra1 is selected from the group consisting of —(CH2)6—, —(CH2)7—, —(CH2)8—, —(CH2)9—, and —(CH2)10—;each of Rb1, Rb1′, Rb2 and Rb2′ are the same, and are selected from the group consisting of —(CH2)—,—(CH(CH3)2) and —(CH3);Rc1 is selected from the group consisting of —(CH2)4—, —(CH2)5—, —(CH2)6—, —(CH2)7—, and —(CH2)8—;andRc2 is selected from the group consisting of where z is 0, 1, or 2. 10. The device of claim 9, wherein for the polymer Ra1 is —(CH2)8—;Rb1 Rb1′ Rb2 and Rb2′ the same and are —(CH2)—(CH(CH3)2) ;Rc1 is —(CH2)6—;Rc2 is and s1 is 0.5, and t1 is between 0.125 and 0.375. 11. The device of claim 9, wherein the peptide or protein is cRGD, and the hydrophobic drug is everolimus. 12. The device of claim 11, wherein the mass ratio of (protein or peptide): hydrophobic drug: polymer is about 1:1:3. 13. The device of claim 1, wherein the hydrophobic drug is selected from the group consisting of sirolimus (rapamycin), biolimus A9, deforolimus, AP23572 (Ariad Pharmaceuticals), tacrolimus, temsirolimus, pimecrolimus, zotarolimus (ABT-578), 40- O-(2-hydroxy)ethyl-rapamycin (everolimus), 40-O-(3-hydroxypropyl)rapamycin, 40-O- [2-hydroxy)ethoxy]ethyl-rapamycin, 40-O-tetrazole-rapamycin, 40-O-tetrazolylrapamycin, 40-epi-(N1-tetrazole)-rapamycin, paclitaxel, docetaxel, estradiol, 17-beta-estradiol, nitric oxide donors, super oxide dismutases, super oxide dismutases mimics, 4-amino-2,2,6,6-tetramethylpiperidine-1-oxyl (4-amino-TEMPO), dexamethasone, γ-hiridun, clobetasol, dexamethasone acetate, mometasone, imatinib mesylate, midostaurin, feno fibrate, feno fibric acid, and prodrugs thereof, co-drugs thereof, and combinations thereof. 14. The device of claim 13, wherein the hydrophobic drug is everolimus. 15. The device of claim 13, wherein the hydrophobic drug is zotarolimus. 16. The device of claim 1, wherein the hydrophobic drug is an anti-proliferative. 17. The device of claim 1, wherein the peptide or protein is selected from the group consisting of cRGD, other similar size peptides and combinations thereof. 18. The device of claim 1, wherein the peptide or protein is selected from the group consisting of RGD, an RGD peptide, a cyclic RGD peptide (cRGD), a synthetic cyclic RGD (cRGD) mimetic, or a synthetic RGD mimetic and combinations thereof 19. The device of claim 18, wherein the peptide or protein is cRGD. 20. The device of claim 1, wherein the drug reservoir layer is between about 0.5 and about 9 μm in thickness. 21. The device of claim 1, wherein the mass ratio of (protein or peptide): hydrophobic drug: polymer is about 1:1:3. 22. An implantable medical device comprising: a device body and a coating disposed over the device body, the coating comprising; a drug reservoir layer comprising: a peptide or protein;a hydrophobic drug;a polymer with a weight average molecular weight between about 10 to about 150 K Daltons;wherein the mass ratio of the peptide or protein to the hydrophobic drug is about 1:0.1 to about 1:10;wherein the ratio of the sum of the mass of peptide or protein and the mass of the hydrophobic drug to the mass of the polymer is about 1:1 to about 1:12;wherein the drug reservoir layer thickness is between about 0.5 and about 7 μm in thickness; andwherein the polymer is poly(ester-amide) that is a random copolymer having the formula: wherein:A1 has the chemical structure: each of B1 and B2 has the chemical structure where j =1 for B1 and j =2 for B2;s1, t1, and t2 represent the average mole fraction of each of A1, B1, and B2;t1 is between 0.125 and 0.375;t2 =0.5 −t1;s1 =0.5; andp is an integer from 2 to about 4500;wherein: Ra1 is selected from the group consisting of —(CH2)6—, —(CH2)7—, —(CH2)8—,—(CH2)9—, and ——(CH2)10 —;each of Rb1 Rb1′ , Rb2 and Rb2′ are the same, and are selected from the group consisting of —(CH2)—(CH(CH3)2) and —(CH3);Rc1 is selected from the group consisting of —(CH2)4—,—(CH2)5—, —(CH2)6—,—(CH2)7—, and —(CH2)8—; andRc2 is selected from the group consisting of where z is 0, 1, or 2. 23. The device of claim 22, wherein the hydrophobic drug is selected from the group consisting of sirolimus (rapamycin), biolimus A9, deforolimus, AP23572 (Ariad Pharmaceuticals), tacrolimus, temsirolimus, pimecrolimus, zotarolimus (ABT-578), 40-O-(2-hydroxy)ethyl-rapamycin (everolimus), 40-O-(3-hydroxypropyl)rapamycin, 40-O-[2-hydroxy)ethoxy]ethyl-rapamycin, 40-O-tetrazole-rapamycin, 40-O-tetrazolylrapamycin, 40-epi-(N1-tetrazole)-rapamycin, paclitaxel, docetaxel, estradiol, 17-beta-estradiol, nitric oxide donors, super oxide dismutases, super oxide dismutases mimics, 4-amino-2,2,6,6-tetramethylpiperidine-1-oxyl (4-amino-TEMPO), dexamethasone, γ-hiridun, clobetasol, dexamethasone acetate, mometasone, imatinib mesylate, midostaurin, feno fibrate, feno fibric acid, and prodrugs thereof, co-drugs thereof, and combinations thereof. 24. The device of claim 22, wherein the peptide or protein is selected from the group consisting of RGD, an RGD peptide, a cyclic RGD peptide (cRGD), a synthetic cyclic RGD (cRGD) mimetic, a synthetic RGD mimetic, other similar size peptides, and combinations thereof. 25. A method of fabricating a coated implantable medical device comprising: providing an implantable medical device;providing a peptide or protein, a hydrophobic drug, and a polymer with a weight average molecular weight between about 10,000 to about 150,000 Daltons;dissolving or dispersing the peptide or protein, the hydrophobic drug, and the polymer in ethanol wherein the mass ratio of the peptide or protein to the hydrophobic drug is from about 1:0.1 to about 1:10; and wherein the mass ratio of the protein or peptide to the polymer is from about 1:0.1 to about 1:10;applying the ethanol solution/dispersion to the implantable medical device; andremoving the ethanol to form a drug reservoir layer;wherein the cumulative release of the peptide or protein from the drug reservoir layer is between about 5% and about 50% at 24 hours and between about 10% and about 95% at 7 days; andwherein the polymer is a poly(ester-amide) or a poly(amide) that is of the following formula: wherein:i is an integer from 1 to 10, inclusive;j is an integer from 0 to 10, inclusive;k is an integer from 0 to 15, inclusive;xn is an integer from 0 to 100, inclusive;ym is an integer from 0 to 150, inclusive;p is an integer from 2 to about 4500;Mw is from about 10,000 to about 1,000,000 Da;s tj, and vk represent the average mole fraction of each of Al, Bj, and Ck;si is a number from 0 to 0.5, inclusive;tj is a number from 0 to 0.5, inclusive;vk is a number from 0 to 0.5, inclusive;with the proviso that Σisi+Σjtj+Σkvk=1.0;Σisi=Σjtj+Σkvk=0.5;Σisi>0;Σjtj>0 or Σkvk>0;each Ai, has the chemical structure: each Bj has the chemical structure and each Ck has the chemical structure: wherein:each Rbj, and Rbj′ are independently selected from the group consisting of hydrogen and (C1-C4)alkyl, wherein: the alkyl group is optionally substituted with a moiety selected from the group consisting of —OH, —SH, —SeH, —C(O)OH, —NHC(NH)NH2, phenyl and or one or more of Rbj and Rbj′ may form a bridge between the carbon to which it is attached and the adjacent nitrogen, the bridge comprising —CH2CH2CH2-;each Rai and each Rcj are independently selected from the group consisting of (C1-C12)alkyl, (C2-C12)alkenyl, (C3-C8)cycloalkyl,—(CH2CH2O)qCH2CH2- wherein q is an integer from 1 to 10, inclusive, and where z is 0, 1, or 2; subject to the restriction that at least one Ra, is selected from the group consisting of where z is 0, 1, or 2; Rdk is selected from the group consisting of —H, —OH, —O(C1-C20)alkyl, —O(C1-C20)alkenyl and —O(CH 2CH2O)wCH2CH2ORek, wherein: w is an integer from 1 to 600, inclusive;Rek is selected from the group consisting of hydrogen,—C(O)CH═CH2 and —C(O)C(CH3)═CH2; and,each Rai, corresponds to the ith Ai group, each Rbj, Rbj′, and Rcj corresponds to the jth Bj group, andeach Rdk and optionally Rek correspond to the kth Ck group. 26. The method of claim 23, wherein the cumulative release of the hydrophobic drug from the drug reservoir layer is between about 5% and about 50% at 24 hours and between about 10% and about 95% at 7 days. 27. The method of claim 23, wherein the cumulative release of the hydrophobic drug from the drug reservoir layer is between 10% and about 35% at 24 hours and between about 25% and about 75% at 7 days. 28. A coated implantable medical device fabricated by the method of claim 25. 29. The device of claim 9, wherein Rc2 is selected from the group consisting of 30. The device of claim 9, wherein the hydrophobic drug is selected from the group consisting of sirolimus (rapamycin), biolimus A9, deforolimus, AP23572 (Ariad Pharmaceuticals), tacrolimus, temsirolimus, pimecrolimus, zotarolimus (ABT-578), 40- O-(2-hydroxy)ethyl-rapamycin (everolimus), 40-O-(3-hydroxypropyl)rapamycin, 40-O-[2-(2-hydroxy)ethoxy]ethyl-rapamycin, 40-O-tetrazole-rapamycin, 40-O-tetrazolylrapamycin, 40-epi-(N1-tetrazole)-rapamycin, paclitaxel, docetaxel, estradiol, 17-beta-estradiol, nitric oxide donors, super oxide dismutases, super oxide dismutases mimics, 4-amino-2,2,6,6-tetramethylpiperidine-1-oxyl (4-amino-TEMPO), dexamethasone, γ-hiridun, clobetasol, dexamethasone acetate, mometasone, imatinib mesylate, midostaurin, feno fibrate, feno fibric acid, and prodrugs thereof, co-drugs thereof, and combinations thereof; andthe peptide or protein is selected from the group consisting of RGD, an RGD peptide, a cyclic RGD peptide (cRGD), a synthetic cyclic RGD (cRGD) mimetic, a synthetic RGD mimetic, other similar size peptides, and combinations thereof. 31. A method of fabricating a coated implantable medical device comprising: providing an implantable medical device;providing a peptide or protein, a hydrophobic drug, and a polymer with a weight average molecular weight between about 10,000 to about 150,000 Daltons;dissolving or dispersing the peptide or protein, the hydrophobic drug, and the polymer in ethanol wherein the mass ratio of the peptide or protein to the hydrophobic drug is from about 1:0.1 to about 1:10; and wherein the mass ratio of the protein or peptide to the polymer is from about 1:0.1 to about 1:10;applying the ethanol solution/dispersion to the implantable medical device; andremoving the ethanol to form a drug reservoir layer;wherein the cumulative release of the peptide or protein from the drug reservoir layer is between about 5% and about 50% at 24 hours and between about 10% and about 95% at 7 days;andwherein the polymer is a poly(ester-amide) or a poly(amide) that is of the following formula: wherein:si, tj, and vk represent the average mole fraction of each of Ai, Bj, and Ck;i is an integer from 1 to 10, inclusive;j is an integer from 0 to 10, inclusive;k is an integer from 0 to 15, inclusive;xn is an integer from 0 to 100, inclusive;ym is an integer from 0 to 150, inclusive;p is an integer from 2 to about 4500;Mw is from about 10,000 to about 1,000,000 Da;si is a number from 0 to 0.5, inclusive;tj is a number from 0 to 0.5, inclusive;vk is a number from 0 to 0.5, inclusive;with the proviso that Σisi+Σjtj+Σkvk=1.0;Σisi=Σjtj+Σkvk=0.5;Σisi>0;Σjtj>0 or Σkvk>0;each A, has the chemical structure: each Bj has the chemical structure and each Ck has the chemical structure: each Rai corresponds to the ith Ai group, each Rbj, Rbj′, and Rcj corresponds to the jth Bj group, andeach Rdk and optionally Rek correspond to the kth Ck group; and wherein i=1, j=2, k=0, Ra1 is selected from the group consisting of —(CH2)6—, —(CH2)7—, —(CH2)8—, —(CH2)9—, and (CH2)10—;each of Rb1, Rb1′, Rb2 and Rb2′ are the same, and are selected from the group consisting of —(CH2)—(CH(CH3)2) and —(CH3);Rc1 is selected from the group consisting of —(CH2)4—, —(CH2)5—, (CH2)6—, —(CH2)7—, and —(CH2)8—; andRc2 is selected from the group consisting of where z is 0, 1, or 2. 32. A coated implantable medical device fabricated by the method of claim 31.